Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Queensland Health
Johnson and Johnson
Medtronic
Moodys
Mallinckrodt
Accenture
Express Scripts
Cipla

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,829,120

« Back to Dashboard

Which drugs does patent 7,829,120 protect, and when does it expire?

Patent 7,829,120 protects OLEPTRO and is included in one NDA.

This patent has forty patent family members in twenty-four countries.
Summary for Patent: 7,829,120
Title:Trazodone composition for once a day administration
Abstract:The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.
Inventor(s): Gervais; Sonia (Laval, CA), Smith; Damon (Saint-Laurent, CA), Rahmouni; Miloud (Pierrefonds, CA), Contamin; Pauline (Magny En Vexin, FR), Ouzerourou; Rachid (Anjou, CA), Ma; My Linh (Saint-Laurent, CA), Ferrada; Angela (Montreal, CA), Soulhi; Fouzia (Dollard-des-Ormeaux, CA)
Assignee: Labopharm Inc. (Quebec, CA) Labopharm Europe Limited (Dublin, IE) Labopharm (Barbados) Limited (St. Michael, BB)
Application Number:11/519,194
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Delivery; Use; Formulation;

Drugs Protected by US Patent 7,829,120

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Angelini Pharma OLEPTRO trazodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022411-001 Feb 2, 2010 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y METHOD OF TREATING DEPRESSION ➤ Try a Free Trial
Angelini Pharma OLEPTRO trazodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022411-002 Feb 2, 2010 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y METHOD OF TREATING DEPRESSION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,829,120

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,962,019 Sustained drug release composition ➤ Try a Free Trial
9,439,866 Trazodone composition for once a day administration ➤ Try a Free Trial
8,414,919 Sustained drug release composition ➤ Try a Free Trial
8,795,723 Sustained drug release compositions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,829,120

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 059678 ➤ Try a Free Trial
Argentina 059682 ➤ Try a Free Trial
Australia 2006308448 ➤ Try a Free Trial
Australia 2006308449 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Deloitte
Merck
Chinese Patent Office
AstraZeneca
Medtronic
Teva
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.